HIGHBuilt-inGeographic
New York and New Jersey
“10-K Item 1: 'Our clinical and women's health testing services are concentrated in New York and New Jersey.'”
OPK · Concentration risk · 10-K extracted
Opko Health (OPK) concentration risks
Updated
The most significant concentration Opko Health discloses is New York and New Jersey, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Opko Health’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 2 disclosed concentrations
HIGH2
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHOutside partyCounterparty
Pfizer
“10-K Item 1A: 'Our exclusive worldwide agreement with Pfizer is important to our business.'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06Opko Health carries two high-scale, structurally distinct concentrations. Its clinical and women's health testing services are geographically concentrated in New York and New Jersey, a structural exposure that ties a meaningful part of the business to the regulatory, competitive, and demographic conditions of those two states specifically rather than a national testing footprint. Separately, the company describes its exclusive worldwide agreement with Pfizer as important to its business, a high-scale counterparty dependency on a single partner. These two exposures are different in kind and largely independent of one another: the New York/New Jersey concentration is a structural, market-specific risk tied to Opko's testing operations, while the Pfizer relationship is an idiosyncratic counterparty risk tied to a specific commercial agreement. Because both are disclosed as high in scale, either one could meaningfully affect results — a regulatory or competitive shift in the testing business's core states, or any disruption to the Pfizer agreement, would each represent a significant, distinct risk to different parts of the business rather than a single combined exposure.
For the engine’s reasoning on OPK’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Diagnostics & Research
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ADPT | Adaptive Biotechnologies Corpor | 2 | 0 | 0 | 2 |
| OPK● | Opko Health, Inc. | 2 | 0 | 0 | 2 |
| CDNA | CareDx, Inc. | 1 | 1 | 0 | 2 |
| CRL | Charles River Laboratories Inte | 1 | 1 | 0 | 2 |
| BLLN | BillionToOne, Inc. | 1 | 0 | 0 | 1 |
| A | Agilent Technologies, Inc. | 0 | 1 | 0 | 1 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.